1 Introduction
Unequivocal renal function determination is pivotal in many clinical situations. In the renal transplantation setting, this is particularly true for living renal transplant donor eligibility screening and renal transplant function monitoring, as well as for research purposes.
Initial screening of living renal transplant donor candidates and routine monitoring of renal transplant recipients is typically performed with 24-h urinary creatinine clearance or by estimation of the glomerular filtration rate (GFR) using serum creatinine and an estimation formula (eGFR
cr) [
1,
2]. Although eGFR
cr has provided a convenient renal function marker for decades, it shows poor agreement with measured GFR (mGFR) techniques, which are considered to correspond best with the true GFR [
3,
4]. However, 24-h urinary creatinine clearance is considered cumbersome owing to the challenge of collecting and transporting the timed urine collection [
1]. In donor candidate screening, this poses a challenge when determining the eligibility of donor candidates with borderline 24-h urinary creatinine clearance or eGFR
cr, typically within the 60–90 mL/min/1.73 m
2 range [
1,
3]. In recipients, it may render eGFR
cr to be of limited informative value to monitor transplant function over time [
2,
3]. International guidelines on donor screening and recipient care acknowledge the limited reliability of eGFR
cr for these purposes and identify mGFR techniques, which utilise urinary or plasma clearance of exogenous filtration markers, superior in terms of accuracy [
1‐
4]. Although mGFR techniques are generally considered the gold standard for renal function assessment, these can prove burdensome because of their dependency on extensive sampling [
3,
5]. This limits the clinical feasibility of mGFR and has hampered its widespread use in routine clinical practice. In recent years, mGFR based on single-dose iohexol plasma clearance has, nonetheless, gained particular clinical interest and is advocated as an alternative for routine renal function evaluation [
3‐
5].
In conventional iohexol mGFR methods, iohexol is administered via a single intravenous bolus injection [
6,
7]. Iohexol plasma clearance is then quantified from the full area under the concentration–time curve (AUC), determined by either extensive sampling or sparse sampling during the terminal log-linear elimination phase with subsequent extrapolation to the full AUC using the Brøchner–Mortensen or Jacobsson equation [
7‐
9]. Whereas these methods provide clinically feasible approaches for iohexol GFR determination, they are based on estimations guided by the terminal elimination phase exclusively [
6]. Furthermore, these methods continue to rely on extensive sampling or late samples drawn up to 8 h after iohexol administration [
6,
7], which still encompasses a large patient burden.
A pharmacometric approach could likely provide a more accurate and robust iohexol GFR estimation, as this technique can capture its entire pharmacokinetic profile. Moreover, it facilitates the development of limited sampling schedules (LSSs) drawn early after iohexol administration to aid clinical application. Indeed, a previously published pharmacometric model showed adequate GFR predictive ability, utilising Bayesian forecasting with four blood samples drawn within 5 h after iohexol administration [
10]. Notably, sampling up to 5 h was required for adequate estimation reliability for GFRs below 30 mL/min [
10]. As renal transplant recipients and particularly donor candidates typically show GFRs exceeding 30 mL/min, this likely allows for application of shorter sampling schemes in this population to further increase iohexol mGFR feasibility.
Here, we aim to develop a population pharmacokinetic model and LSSs for iohexol to provide a pragmatic tool for iohexol GFR determination in the renal transplantation setting. Additionally, we incorporate the model in an online precision dosing platform to further aid its clinical application.
4 Discussion
A population pharmacokinetic model and LSSs for iohexol mGFR estimation in renal transplant recipients and living renal transplant donor candidates were developed. Our approach enables pragmatic mGFR determination for donor candidate eligibility screening and renal transplant function monitoring for clinical and research purposes. This is the first study to describe the population pharmacokinetics of iohexol in donor candidates and the third for recipients [
30,
31]. Furthermore, the study provides clinically feasible LSSs based on three to four blood draws within 3–4 h after iohexol administration, whereas previous studies reported LSSs that relied on sampling up to 4.5–5 h [
10,
31]. Finally, we implemented our model in a validated point-of-care precision dosing platform, which facilitates its application in clinical practice, especially when integrated with local electronic medical record software.
A two-compartmental model adequately captured the concentration–time data, showing good resemblance between individual predicted and measured iohexol concentrations in the development and validation cohorts. Allometric scaling of all flow and volume parameters to FFM and the inclusion of patient type as a covariate on
CL and
Vc improved the model and its individual predictions. During internal validation, some divergence regarding the BSVs of
Q and
Vc, was apparent. The individual predictive performance combined with good stability of
CL and
Vc did, however, provide reassurance that the model is fit for purpose, which was confirmed in the external validation. Comparison of our model-predicted GFR against the GFR
bm showed adequate method agreement in the 30–90 mL/min range. Agreement in the higher GFR range was moderate, likely explained by incremental GFR underprediction of the GFR
bm at higher GFRs [
6,
28].
Previously published population pharmacokinetic models for iohexol comprised one-compartmental [
30], two-compartmental [
10,
31,
32] and three-compartmental models [
33]. Taubert et al. showed that their initial two-compartmental population model based on data from 570 elderly patients displayed underprediction in the early distribution phase, which was resolved in a three-compartmental model [
33]. Efforts into fitting a three-compartmental model to our data, however, resulted in overparameterisation. Benz-de Bretagne et al. developed a one-compartmental model in 95 renal transplant recipients, but this model described only the terminal log-linear elimination phase and still relied on Brøchner–Mortensen extrapolation [
30]. Riff et al
. developed a model in 151 renal transplant recipients with pharmacokinetic data up to 4.5 h after administration, and developed 3-point LSSs with data from 8 to 22 patients [
31]. Notably, their LSSs were not validated for patients with GFRs below 30 mL/min [
31]. Moreover, the limited number of patients complicates interpretation of their overall validity [
31]. Åsberg et al. developed their model in 219 patients with pharmacokinetic data up to 24 h [
10]. Their 4-point LSS within 5 h showed excellent predictive performance for GFRs of 14–149 mL/min, whereas a 3-h LSS showed unacceptable extents of bias and imprecision in the lower GFR range [
10]. Application of their 5-h LSS with our model yielded similar predictive performance as observed for our 4-h LSSs, confirming that deprecated sampling up to 4 h is possible without impairing LSS performance in our population with GFRs exceeding 30 mL/min. Ultimately, selection of an appropriate model and LSS should be guided by the trade-off between clinical pragmatism and LSS predictive performance, on which considerations may vary across clinical situations and centres.
Our study showed some limitations. First, most pharmacokinetic data originated from subjects with estimated GFRs between 30 and 150 mL/min, drawn up to 4 h after iohexol administration. Whereas most of the iohexol AUC is captured within this 4-h time frame for most of these patients, the model would ideally have been based on full iohexol pharmacokinetic profiles from subjects across the entire GFR range. Unfortunately, limited data from patients with GFRs below 30 mL/min were available, thwarting model and LSS development for this GFR range. This warrants adaptation and validation of our model and LSS for renal transplant recipients with a GFR < 30 mL/min before considering this technique for these patients, which could be valuable for clinical decisions concerning dialysis and medication and dose adaptation. In contrast, the model and LSSs were successfully developed and validated for GFRs between 30 and 150 mL/min, which captures most renal transplant recipients and living renal transplant donor candidates. Moreover, the majority of donor eligibility decisions and longitudinal renal transplantation research, and part of renal function-guided clinical decisions regarding medication and dose adaptation, for which mGFR determination shows particular added value over conventional eGFR assessment, occur in subjects with GFRs exceeding 30 mL/min. This limitation thus only slightly narrows the added value of our technique. Second, our approach assumes iohexol to be fully cleared renally, whereas a small portion of iohexol (< 5%) undergoes non-renal excretion [
4]. Additional validation against, for instance, urinary inulin clearance could have provided additional insight in the accuracy of our approach. Third, small deviations between the prescribed iohexol doses and the actually administered doses may have occurred, as the syringes were not weighed before and after administration as suggested previously [
10]. This may have contributed to the residual error, although the contributions of measurement errors and small sampling time reporting deviations, especially early after iohexol administration, are likely more important. Fourth, part of our study was based on simulations beyond 4 h after iohexol administration. As the model was developed and thoroughly validated using pharmacokinetic data up to 4 h exclusively, simulations beyond 4 h may be associated with additional uncertainty. This uncertainty, however, is likely limited given the rather standard terminal log-linear clearance of iohexol, and the demonstrated ability of the model to adequately fit curves beyond 4 h. Fifth, InsightRX is only accessible with a license, which may pose a hurdle for applying our tool as compared to open-source solutions. In contrast, such a professional platform guarantees a certified and validated tool with sustained end-user support, adequate maintenance, data safety and flexibility to adapt to local situations, whereas open-source solutions are not seldomly short-lived owing to insufficient maintenance, limited end-user support and low flexibility. Moreover, clinical laboratory accreditation requirements demand such dosing tools to be certified and validated, which poses an important hurdle for realising open-source solutions. Last, it is important to acknowledge that mGFR, including urinary inulin clearance, also introduces bias in comparison to the true GFR and that outcomes may vary across markers and laboratory sites [
34].
Additional possibilities to aid the clinical application of iohexol mGFR in renal transplant recipients include microsampling. We have previously developed a volumetric dried blood spot method for remote tacrolimus and mycophenolic acid exposure monitoring [
29]. As tacrolimus and mycophenolate exposure are estimated using the trough, 1-, 2- and 3-h concentrations [
29], the T5T60T120T180 iohexol LSS could allow for blood draw alignment. Incorporation of iohexol in the multiplex immunosuppressant assay could then allow for simultaneous (partially) remote renal function and immunosuppressant monitoring. This may provide options for further reducing patient burden and costs, as patients would only have to come to the outpatient clinic for iohexol administration and the first sample and perform the remaining samples remotely. Furthermore, remote microsampling may enable pragmatic extended iohexol sampling for patients with impaired renal function.
Last, our approach could be interesting for application in other populations. As living renal transplant donor candidates are mostly healthy individuals across the adult age range, it seems valid to apply the model and LSSs for renal evaluation in healthy volunteers as these generally show similar renal functions. This could particularly be valuable for research purposes [
4]. Healthy volunteer populations, however, usually show an overrepresentation of young male individuals, which may warrant external model validation.